EP4387964A1 — Jak2 inhibitors and methods of use thereof
Assigned to Relay Therapeutics Inc · Expires 2024-06-26 · 2y expired
What this patent protects
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of JAK2 enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for …
USPTO Abstract
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of JAK2 enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with JAK2 signaling with the compounds and compositions of the disclosure.
Drugs covered by this patent
- Sotyktu (DEUCRAVACITINIB) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.